sr141716 has been researched along with Encephalopathy, Toxic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dang, DK; Jang, CG; Jeong, JH; Kim, HC; Ledent, C; Mai, AT; Nabeshima, T; Nah, SY; Onaivi, ES; Shin, EJ; Yamamoto, T | 1 |
| Cheer, JF; Glick, SD; Morra, JT | 1 |
| Bissonnette, CJ; Klegeris, A; McGeer, PL | 1 |
3 other study(ies) available for sr141716 and Encephalopathy, Toxic
| Article | Year |
|---|---|
Genetic or pharmacological depletion of cannabinoid CB1 receptor protects against dopaminergic neurotoxicity induced by methamphetamine in mice.
Topics: Animals; Apoptosis; Butadienes; Cells, Cultured; Corpus Striatum; Dopamine; Extracellular Signal-Regulated MAP Kinases; Methamphetamine; Mice; Mice, Inbred C57BL; Mice, Knockout; Neurotoxicity Syndromes; Nitriles; Oxidative Stress; Piperidines; Protein Kinase C-delta; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, Dopamine D2; Rimonabant; Sulpiride | 2017 |
Cannabinoid receptors mediate methamphetamine induction of high frequency gamma oscillations in the nucleus accumbens.
Topics: Animals; Brain Waves; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Central Nervous System Stimulants; Disease Models, Animal; Dose-Response Relationship, Drug; Interneurons; Male; Methamphetamine; Nerve Tissue Proteins; Neurotoxicity Syndromes; Nucleus Accumbens; Piperidines; Psychomotor Performance; Psychotic Disorders; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptors, Cannabinoid; Rimonabant | 2012 |
Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor.
Topics: Astrocytes; Camphanes; Cannabinoid Receptor Modulators; Cannabinoids; Cell Line; Cytokines; Dronabinol; Formazans; Gene Expression; Humans; Indoles; Indomethacin; L-Lactate Dehydrogenase; Ligands; Microglia; Monocytes; Morpholines; Nerve Degeneration; Neurotoxicity Syndromes; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Reverse Transcriptase Polymerase Chain Reaction; Rimonabant; RNA, Messenger; Temporal Lobe; Tetrazolium Salts | 2003 |